Brief: Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2-Years, Affirming Its Use As A Powerful First Line Systemic Therapy
02/10/2026 11:03
BRIEF-Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2-Years, Affirming Its Use As A Powerful First Line Systemic Therapy Oct 2 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON ANNOUNCES NEW ICOTYDE® (ICOTROKINRA) DATA IN DIFFICULT-TO-TREAT PLAQUE PSORIASIS WITH PROVEN DURABILITY THROUGH 2-YEARS, AFFIRMING ITS USE AS A POWERFUL FIRST LINE SYSTEMIC THERAPY~
J&J - 60% SCALP PSORIASIS, 89% GENITAL PSORIASIS PATIENTS ACHIEVE COMPLETE CLEARANCE AT WEEK 112
J&J - SAFETY FINDINGS THROUGH WEEK 112 CONSISTENT WITH ICOTYDE PROFILE, NO NEW SAFETY SIGNALS
J&J - ICOTYDE-TREATED PATIENTS SHOW 70% CLEAR OR ALMOST CLEAR SKIN AT WEEK 112
Source text: ID:nPn60m6VZa
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Johnson & Johnson
See all newsEli Lilly hits record high as healthcare stocks rally
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived (updated)
Brief: Johnson & Johnson Announces New Data For Tremfya
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin